Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and Intra-Cellular Therapies to develop schizophrenia drugs

Takeda and Intra-Cellular Therapies to develop schizophrenia drugs

8th March 2011

Takeda is allying with Intra-Cellular Therapies on the development of new compounds with potential promise in treating cognitive impairment associated with schizophrenia.

The agreement will see Intra-Cellular Therapies receive up to $750 million (463.6 million pounds) for development rights to its selective phosphodiesterase type 1 inhibitor compounds.

It is thought that the unique orally-available agents, which are currently in the preclinical development stage, have the potential to be effective against an array of psychiatric and neurological impairments.

The deal will allow Takeda to commercialise any resulting products worldwide, though Intra-Cellular Therapies retains the option to co-promote the drugs in the US.

Shigenori Ohkawa, executive vice-president and chief scientific officer of Takeda, said: "We plan to accelerate our research and development activities for this compound in an effort to bring this novel medicine to patients as quickly as possible."

Last month, the company announced that it has hired contract research organisations Covance and Quintiles to assist it with its drug development programmes over the coming years.ADNFCR-8000103-ID-800448245-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.